Rohan Fernandes Selected Research

ferric ferrocyanide (Prussian blue)

3/2022	The Thermal Dose of Photothermal Therapy Generates Differential Immunogenicity in Human Neuroblastoma Cells.
8/2021	An Engineered Prussian Blue Nanoparticles-based Nanoimmunotherapy Elicits Robust and Persistent Immunological Memory in a TH-MYCN Neuroblastoma Model.
10/2020	CpG-coated prussian blue nanoparticles-based photothermal therapy combined with anti-CTLA-4 immune checkpoint blockade triggers a robust abscopal effect against neuroblastoma.
4/2019	Prussian blue nanoparticle-based antigenicity and adjuvanticity trigger robust antitumor immune responses against neuroblastoma.
1/2018	Photothermal Therapy Generates a Thermal Window of Immunogenic Cell Death in Neuroblastoma.
1/2017	Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma.
1/2017	Composite iron oxide-Prussian blue nanoparticles for magnetically guided T1-weighted magnetic resonance imaging and photothermal therapy of tumors.
1/2014	Manganese-containing Prussian blue nanoparticles for imaging of pediatric brain tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rohan Fernandes Research Topics

Disease

16	Neoplasms (Cancer) 03/2022 - 11/2016
8	Neuroblastoma 03/2022 - 01/2017
2	Melanoma (Melanoma, Malignant) 01/2020 - 01/2020
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 03/2020
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2020
1	Breast Neoplasms (Breast Cancer) 01/2020
1	HIV Infections (HIV Infection) 01/2020
1	Glioblastoma (Glioblastoma Multiforme) 01/2017
1	Neurofibrosarcoma (MPNST) 11/2016
1	Neurofibromatoses (Neurofibromatosis) 11/2016
1	Pathologic Processes 10/2016
1	Pre-Eclampsia (Preeclampsia) 10/2016
1	Brain Neoplasms (Brain Tumor) 01/2014

Drug/Important Bio-Agent (IBA)

8	ferric ferrocyanide (Prussian blue)FDA Link 03/2022 - 01/2014
3	AntigensIBA 03/2022 - 10/2020
3	Immune Checkpoint InhibitorsIBA 12/2020 - 01/2020
2	OligodeoxyribonucleotidesIBA 08/2021 - 04/2019
2	Polylactic Acid-Polyglycolic Acid CopolymerIBA 03/2020 - 01/2020
2	Biological ProductsIBA 11/2016 - 10/2016
1	LigandsIBA 03/2022
1	Immune Checkpoint ProteinsIBA 03/2022
1	Immunologic Adjuvants (Immunologic Adjuvant)IBA 08/2021
1	Monoclonal AntibodiesIBA 12/2020
1	diazonaphthalenedisulfonic acid (NDS)IBA 03/2020
1	prostratinIBA 03/2020
1	4- ((1- butyl- 3- phenylureido)methyl)- N- hydroxybenzamideIBA 01/2020
1	Histone Deacetylases (Histone Deacetylase)IBA 01/2020
1	Indocyanine Green (Cardio-Green)FDA LinkGeneric 01/2020
1	Cytotoxins (Cytolysins)IBA 01/2020
1	Histone Deacetylase InhibitorsIBA 01/2020
1	Neoplasm Antigens (Tumor Antigens)IBA 04/2019
1	Contrast MediaIBA 01/2017
1	PerforinIBA 01/2017
1	ferric oxide (iron oxide)IBA 01/2017
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2017
1	GadoliniumIBA 01/2017
1	CytokinesIBA 01/2017
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 11/2016
1	Epidermal Growth Factor (EGF)IBA 10/2016
1	ManganeseIBA 01/2014

Therapy/Procedure

10	Photothermal Therapy 03/2022 - 11/2016
6	Immunotherapy 03/2022 - 11/2016
5	Therapeutics 08/2021 - 01/2019
1	Lasers (Laser) 01/2020
1	Highly Active Antiretroviral Therapy (HAART) 01/2020
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2019
1	Precision Medicine 01/2017